Physicians and researchers at Emory University’s Winship Cancer Institute administered the first investigational in vivo CAR-T cell therapy dose in the United States for relapsed or refractory multiple myeloma. The study targets disease that has progressed after prior treatments, marking a milestone for next-generation cellular approaches designed to avoid full cell manufacturing workflows. The investigational program is positioned as a U.S. first for an in vivo CAR-T strategy—where CAR components are delivered into the patient to enable endogenous targeting machinery rather than ex vivo engineered T-cell infusion. The report frames the dose as a step toward broader clinical validation. For biotech stakeholders, the event underscores how “in vivo” CAR platforms are moving from concept to regulated clinical dosing and expanding the competitive landscape beyond traditional ex vivo manufacturing.